Loading...
•
Dec 31, 2020
Travere Q4 2020 Earnings Report
Travere Therapeutics reported its financial results for the fourth quarter and full year 2020.
Key Takeaways
Travere Therapeutics reported Q4 2020 net product sales of $51.0 million, compared to $46.7 million for the same period in 2019. The company's research and development expenses for the fourth quarter of 2020 were $38.4 million, compared to $36.4 million for the same period in 2019. Net loss for the fourth quarter of 2020 was $121.6 million, or $2.37 per basic share, compared to a net loss of $30.3 million for the same period in 2019.
The Company recently reported that the ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment
The Phase 3 PROTECT Study of sparsentan in IgA nephropathy (IgAN) remains on-track to report topline data from the 36-week proteinuria analysis in the third quarter of 2021
Completed acquisition of TVT-058 (previously OT-58), an investigational human enzyme replacement therapy with disease modifying potential in Phase 1/2 development for the treatment of classical homocystinuria (HCU)
Net product sales for the fourth quarter of 2020 were $51.0 million, compared to $46.7 million for the same period in 2019
Revenue by Segment
Forward Guidance
In 2021, the Company anticipates mid-single-digit percentage growth in net product sales compared to 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...